28.04.2014 • News

Zimmer to Buy Biomet for $13.35 Billion

U.S.-based Zimmer Holdings has said it will buy rival orthopedic products maker Biomet for more than $13 billion, the latest deal in a wave of consolidations in the healthcare industry.

It is also the latest successful exit for private equity. In 2007, Biomet was acquired for $11.3 billion by Blackstone, Goldman Sachs's buyout group, Kohlberg Kravis Roberts and TPG Capital.

The deal is expected to take Zimmer from the fourth-largest seller of orthopedics products to no. 2, behind Johnson & Johnson.

Zimmer, which expects to close the deal in the first quarter of 2015, said the combination would double the size of its spine and dental business, broaden its portfolio of products to treat bones, knees and hips, and give it an entry into the smaller but growing field of sports medicine.

The deal will also significantly add to the company's earnings in the first year and is expected to lead to net annual cost savings of about $270 million by the third year after closing.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.